Outcomes measures in idiopathic intracranial hypertension

References

• Mollan SP, Davies B, Silver NC, et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry. 2018;89(10):1088–1100.
   PubMed Web of Science ®Google Scholar
• Virdee J, Larcombe S, Vijay V, et al. Reviewing the RECENT DEVELOPMENTS IN IDIOPATHIC INTRACRANIAL HYPERTENSION. Ophthalmol Ther. 2020;9(4):767–781. .
   PubMed Web of Science ®Google Scholar
• Andrews LE, Liu GT, Ko MW. Idiopathic intracranial hypertension and obesity. Horm Res Paediatr. 2014;81(4):217–225.
   PubMed Web of Science ®Google Scholar
• Mollan SP, Tahrani AA, Sinclair AJ. The potentially modifiable risk factor in idiopathic intracranial hypertension: body weight. Neurol Clin Pract. 2021;10 ( 1212/CPJ.0000000000001063).
   Google Scholar
• Mulla Y, Markey KA, Woolley RL, et al. Headache determines quality of life in idiopathic intracranial hypertension. J Headache Pain. 2015;16(1):521.
   PubMed Web of Science ®Google Scholar
• Mollan SP, Aguiar M, Evison F, et al. The expanding burden of idiopathic intracranial hypertension. Eye (Lond). 2019;33(3):478–485.
   PubMed Web of Science ®Google Scholar
• Adderley NJ, Subramanian A, Nirantharakumar K, et al. Association between idiopathic intracranial hypertension and risk of cardiovascular diseases in women in the United Kingdom. JAMA Neurol. 2019;76(9):1088–1098. .
   PubMed Web of Science ®Google Scholar
• McCluskey G, Doherty-Allan R, McCarron P, et al. Meta-analysis and systematic review of population-based epidemiological studies in idiopathic intracranial hypertension. Eur J Neurol. 2018;25(10):1218–1227.
   PubMed Web of Science ®Google Scholar
• Ghaffari-Rafi A, Mehdizadeh R, Ko AWK, et al. Idiopathic intracranial hypertension in the United States: demographic and socioeconomic disparities. Front Neurol. 2020;11:869.
   PubMed Web of Science ®Google Scholar
• Piper RJ, Kalyvas AV, Young AM, et al. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev. 2015; (8):CD003434. 10.1002/14651858.CD003434.pub3.
   PubMed Web of Science ®Google Scholar
• Sinclair AJ, Burdon MA, Nightingale PG, et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ. 2010;7:341(jul07 2):c2701. .
   PubMed Web of Science ®Google Scholar
• Celebisoy N, Gokcay F, Sirin H, et al. Treatment of idiopathic intracranial hypertension: topiramate vs. acetazolamide, an open label study. Acta Neurol Scand. 2007;116(5):322–327.
   PubMed Web of Science ®Google Scholar
• Ball AK, Howman A, Wheatley K, et al. A randomised controlled trial of treatment for idiopathic intracranial hypertension. J Neurol. 2011;258(5):874–881.
   PubMed Web of Science ®Google Scholar
• Wall M, McDermott MP, Kieburtz KD, et al. NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA. 2014;311:1641–1651. 16
   PubMed Web of Science ®Google Scholar
• Yiangou A, Mitchell JL, Fisher C, et al., Erenumab for headaches in idiopathic intracranial hypertension: a prospective open-label evaluation. Headache. 61(1): 157–169. 2021. .
   PubMed Web of Science ®Google Scholar
• Markey K, Mitchell J, Botfield H, et al. 11β-hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial. Brain Commun. 2020;2(1):fcz050.
   PubMedGoogle Scholar
• Gurney SP, Ramalingam S, Thomas A, et al. Exploring the current management idiopathic intracranial hypertension, and understanding the role of dural venous sinus stenting. Eye Brain. 2020;12:1–13.
   PubMed Web of Science ®Google Scholar
• Mollan SP, Mitchell JL, Ottridge R, et al. Bariatric surgery versus community weight management intervention for the treatment of idiopathic intracranial hypertension (IIH:WT): a randomized controlled trial. JAMA Neurol. 2021. Published online April 26. 10.1001/jamaneurol.2021.0659.
   PubMed Web of Science ®Google Scholar
• Mitchell JL, Mollan SP, Walker J et al. A randomised controlled, trial of the GLP-1 receptor agonist exenatide in idiopathic intracranial hypertension. European Headache Federation meeting 2020 14th European Headache Federation Congress 2020: Meeting Abstracts – J Headache Pain 2020 in press.
   Google Scholar
• Mollan S, Hemmings K, Herd CP, et al., What are the research priorities for idiopathic intracranial hypertension? A priority setting partnership between patients and healthcare professionals. BMJ Open. 9(3): e026573. 2019. .
   PubMed Web of Science ®Google Scholar
• Scotton WJ, Mollan SP, Walters T, et al. Characterising the patient experience of diagnostic lumbar puncture in idiopathic intracranial hypertension: a cross-sectional online survey. BMJ Open. 2018;8(5):e020445.
   PubMed Web of Science ®Google Scholar
• Duits FH, Martinez-Lage P, Paquet C, et al. Performance and complications of lumbar puncture in memory clinics: results of the multicenter lumbar puncture feasibility study. Alzheimers Dement. 2016;12(2):154–163.
   PubMed Web of Science ®Google Scholar
• Yiangou A, Mitchell J, Markey KA, et al. Therapeutic lumbar puncture for headache in idiopathic intracranial hypertension: minimal gain, is it worth the pain? Cephalalgia. 2019;39(2):245–253.
   PubMed Web of Science ®Google Scholar
• Engelborghs S, Niemantsverdriet E, Struyfs H, et al. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst). 2017;8(1):111–126.
   PubMedGoogle Scholar
• Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1–211.
   PubMed Web of Science ®Google Scholar
• Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd edition. Cephalalgia. 2004;24(Suppl 1):9–160. .
   PubMed Web of Science ®Google Scholar
• Bø SH, Lundqvist C. Cerebrospinal fluid opening pressure in clinical practice - a prospective study. J Neurol. 2020;267(12):3696–3701.
   PubMed Web of Science ®Google Scholar
• Wakerley BR, Warner R, Cole M, et al. Cerebrospinal fluid opening pressure: the effect of body mass index and body composition. Clin Neurol Neurosurg. 2020;188:105597.
   PubMed Web of Science ®Google Scholar
• Ottridge R, Mollan SP, Botfield H, et al. Randomised controlled trial of bariatric surgery versus a community weight loss programme for the sustained treatment of idiopathic intracranial hypertension: the Idiopathic Intracranial Hypertension Weight Trial (IIH:WT) protocol. BMJ Open. 2017;7(9):e017426. .
   PubMed Web of Science ®Google Scholar
• Mollan SP, Hoffmann J, Sinclair AJ. Advances in the understanding of headache in idiopathic intracranial hypertension. Curr Opin Neurol. 2019;32(1):92–98.
   PubMed Web of Science ®Google Scholar
• Mollan SP, Sinclair AJ. Headache attributed to Idiopathic Intracranial Hypertension (IIH) and persistent post-IIH Headache: a narrative review. Headache. 2021. 10.1111/head.14125
   PubMed Web of Science ®Google Scholar
• Digre KB, Bruce BB, McDermott MP, et al., Quality of life in idiopathic intracranial hypertension at diagnosis: IIH treatment trial results. Neurology. 84(24): 2449–2456. 2015. .
   PubMed Web of Science ®Google Scholar
• Mollan SP, Spitzer D, Nicholl DJ. Raised intracranial pressure in those presenting with headache. BMJ. 2018;363:k3252.
   PubMed Web of Science ®Google Scholar
• Diener HC, Tassorelli C, Dodick DW, et al. International headache society clinical trials standing committee. Guidelines of the international headache society for controlled trials of acute treatment of migraine attacks in adults: fourth edition. Cephalalgia. 2019;39(6):687–710. .
   PubMed Web of Science ®Google Scholar
• Denton A, Williamson S, Mollan S, et al. Describing the impact of headache in the words of people with idiopathic intracranial hypertension – a qualitative social media study. 14th European Headache Federation Congress 2020: meeting abstracts. J Headache Pain 2020. in press.
   Google Scholar
• Diener HC, Tassorelli C, Dodick DW, et al. International headache society clinical trials committee. Guidelines of the international headache society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia. 2020;40(10):1026–1044. .
   PubMed Web of Science ®Google Scholar
• American Headache Society. The American headache society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59:1–18.
   PubMed Web of Science ®Google Scholar
• Matharu M, Halker R, Pozo-Rosich P, et al. The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis. J Headache Pain. 2017;18(1):78. .
   PubMed Web of Science ®Google Scholar
• Vernieri F, Paolucci M, Altamura C, et al. Onabotulinumtoxin-A in chronic migraine: should timing and definition of non-responder status be revised? Suggestions from a real-life Italian multicenter experience. Headache. 2019;59(8):1300–1309. .
   PubMed Web of Science ®Google Scholar
• Jacobson DM. Intracranial hypertension and the syndrome of acquired hyperopia with choroidal folds. J Neuroophthalmol. 1995;15(3):178–185.
   PubMed Web of Science ®Google Scholar
• Auinger P, Durbin M, Feldon S, et al. OCT Sub-Study Committee for NORDIC Idiopathic Intracranial Hypertension Study Group. Baseline OCT measurements in the idiopathic intracranial hypertension treatment trial, part I: quality control, comparisons, and variability. Invest Ophthalmol Vis Sci. 2014;55:8180–8188.
   PubMed Web of Science ®Google Scholar
• Hoffmann J, Mollan SP, Paemeleire K, et al. European headache federation guideline on idiopathic intracranial hypertension. J Headache Pain. 2018;19(1):93. .
   PubMed Web of Science ®Google Scholar
• Wall M, George D. Visual loss in pseudotumor cerebri. Incidence and defects related to visual field strategy. Arch Neurol. 1987;44(2):170–175.
   PubMedGoogle Scholar
• Smith TJ, Baker RS. Perimetric findings in pseudotumor cerebri using automated techniques. Ophthalmology. 1986;93(7):887–894.
   PubMed Web of Science ®Google Scholar
• Cello KE, Keltner JL, Johnson CA, et al. Factors affecting visual field outcomes in the idiopathic intracranial hypertension treatment trial. J Neuroophthalmol. 2016;36(1):6–12.
   PubMed Web of Science ®Google Scholar
• Wall M, Johnson CA, Cello KE, et al. Visual field outcomes for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). Invest Ophthalmol Vis Sci. 2016;57(3):805–808.
   PubMed Web of Science ®Google Scholar
• Kutzko KE, Brito CF, Wall M. Effect of instructions on conventional automated perimetry. Invest Ophthalmol Vis Sci. 2000;41(7):2006–2013.
   PubMed Web of Science ®Google Scholar
• Ney JJ, Volpe NJ, Liu GT, et al. Functional visual loss in idiopathic intracranial hypertension. Ophthalmology. 2009;116(9):1808–1813.e1.
   PubMed Web of Science ®Google Scholar
• Sørensen PS, Thomsen AM, Gjerris F. Persistent disturbances of cognitive functions in patients with pseudotumor cerebri. Acta Neurol Scand. 1986;73(3):264–268.
   PubMed Web of Science ®Google Scholar
• Kharkar S, Hernandez R, Batra S, et al. Cognitive impairment in patients with pseudotumor cerebri syndrome. Behav Neurol. 2011;24(2):143–148. .
   PubMed Web of Science ®Google Scholar
• Elbanhawy IA, Ramzy GM, Ashour AS, et al. Cognitive assessment of idiopathic intracranial hypertension patients. Egypt J Neurol Psychiatry Neurosurg. 2019;55(1):33.
   Google Scholar
• Elbanhawy IA, Ramzy GM, Basheer MA, et al. Neurophysiologic tests screening cognitive impairment in idiopathic intracranial hypertension patients. Egypt J Neurol Psychiatry Neurosurg. 2018;54(1):7.
   PubMedGoogle Scholar
• Kaplan CP, Miner ME, McGregor JM. Subject review with case study: pseudotumour cerebri risk for cognitive impairment. Brain Inj. 1997;11(4):293–303.
   PubMed Web of Science ®Google Scholar
• Zur D, Naftaliev E, Kesler A. Evidence of multidomain mild cognitive impairment in idiopathic intracranial hypertension. J Neuroophthalmol. 2015;35(1):1.
   PubMed Web of Science ®Google Scholar
• Wall M, Woodward KR, Brito CF. The effect of attention on conventional automated perimetry and luminance size threshold perimetry. Invest Ophthalmol Vis Sci. 2004;45(1):342–350.
   PubMed Web of Science ®Google Scholar
• Henson DB, Emuh T. Monitoring vigilance during perimetry by using pupillography. Invest Ophthalmol Vis Sci. 2010;51(7):3540–3543.
   PubMed Web of Science ®Google Scholar
• Dunn LT. Raised intracranial pressure. J Neurol Neurosurg Psychiatry. 2002 Sep;73(Suppl1):i23–7.
   PubMed Web of Science ®Google Scholar
• Frisén L. Swelling of the optic nerve head: a staging scheme. J Neurol Neurosurg Psychiatry. 1982;45(1):13–18.
   PubMed Web of Science ®Google Scholar
• Waisbourd M, Leibovitch I, Goldenberg D, et al. OCT assessment of morphological changes of the optic nerve head and macula in idiopathic intracranial hypertension. Clin Neurol Neurosurg. 2011;113(10):839–843.
   PubMed Web of Science ®Google Scholar
• Albrecht P, Blasberg C, Ringelstein M, et al. Optical coherence tomography for the diagnosis and monitoring of idiopathic intracranial hypertension. J Neurol. 2017;264(7):1370–1380. .
   PubMed Web of Science ®Google Scholar
• Skau M, Sander B, Milea D, et al. Disease activity in idiopathic intracranial hypertension: a 3-month follow-up study. J Neurol. 2010;258(2):277–283.
   PubMed Web of Science ®Google Scholar
• Vijay V, Mollan SP, Mitchell JL, et al. Using optical coherence tomography as a surrogate of measurements of intracranial pressure in idiopathic intracranial hypertension. JAMA Ophthalmol. 2020;138(12):1264–1271. .
   PubMed Web of Science ®Google Scholar
• Skau M, Yri H, Sander B, et al. Diagnostic value of optical coherence tomography for intracranial pressure in idiopathic intracranial hypertension. Graefes Arch Clin Exp Ophthalmol. 2012;251(2):567–574.
   PubMed Web of Science ®Google Scholar
• Kaufhold F, Kadas EM, Schmidt C, et al. Optic nerve head quantification in idiopathic intracranial hypertension by spectral domain OCT. PLoS One. 2012;7(5):e36965. .
   PubMed Web of Science ®Google Scholar
• Jivraj I, Cruz CA, Pistilli M, et al. Utility of spectral-domain optical coherence tomography in differentiating papilledema from pseudopapilledema: a prospective longitudinal study. J Neuroophthalmol. 2020 Sep 11;Publish Ahead of Print. 10.1097/WNO.0000000000001087
   Web of Science ®Google Scholar
• Minakaran N, De Carvalho ER, Petzold A, et al. Optical coherence tomography (OCT) in neuro-ophthalmology. Eye (Lond). 2021;35(1):17–32.
   PubMed Web of Science ®Google Scholar
• Petzold A, De Boer JF, Schippling S, et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2010;9(9):921–932. .
   PubMed Web of Science ®Google Scholar
• Salgarello T, Falsini B, Tedesco S, et al. Correlation of optic nerve head tomography with visual field sensitivity in papilledema. Invest Ophthalmol Vis Sci. 2001;42(7):1487–1494.
   PubMed Web of Science ®Google Scholar
• Rebolleda G, Muñoz-Negrete FJ. Follow-up of mild papilledema in idiopathic intracranial hypertension with optical coherence tomography. Invest Ophthalmol Vis Sci. 2009;50(11):5197–5200.
   PubMed Web of Science ®Google Scholar
• Afonso CL, Raza AS, Kreuz AC, et al. Relationship between pattern electroretinogram, frequency-domain oct, and automated perimetry in chronic papilledema from pseudotumor cerebri syndrome. Invest Ophthalmol Vis Sci. 2015;56(6):3656–3665.
   PubMed Web of Science ®Google Scholar
• Daniels AB, Liu GT, Volpe NJ, et al. Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol. 2007;143(4):635–641. .
   PubMed Web of Science ®Google Scholar
• Ware JE Jr, Gandek B. Overview of the SF-36 health survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol. 1998;51(11):903–912.
   PubMed Web of Science ®Google Scholar
• Mangione CM, Lee PP, Gutierrez PR, et al. National eye institute visual function questionnaire field test investigators. Development of the 25-item national eye institute visual function questionnaire. Arch Ophthalmol. 2001;119(7):1050–1058. .
   PubMed Web of Science ®Google Scholar
• Raphael BA, Galetta KM, Jacobs DA, et al. Validation and test characteristics of a 10-item neuro-ophthalmic supplement to the NEI-VFQ-25. Am J Ophthalmol. 2006;142(6):1026–1035. .
   PubMed Web of Science ®Google Scholar
• EuroQol Group. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208. .
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370.
   PubMed Web of Science ®Google Scholar
• Kosinski M, Bayliss MS, Bjorner JB, et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003;12(8):963–974. .
   PubMed Web of Science ®Google Scholar
• Thaller M, Tsermoulas G, Sun R, et al. Negative impact of COVID-19 lockdown on papilloedema and idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry. 2020 Dec 24: jnnp-2020-325519. doi10.1136/jnnp-2020-325519.
   PubMed Web of Science ®Google Scholar
• Kleinschmidt JJ, Digre KB, Hanover R. Idiopathic intracranial hypertension: relationship to depression, anxiety, and quality of life. Neurology. 2000;54(2):319–324.
   PubMed Web of Science ®Google Scholar
• Bruce BB, Digre KB, McDermott MP, et al. NORDIC idiopathic intracranial hypertension study group. Quality of life at 6 months in the idiopathic intracranial hypertension treatment trial. Neurology. 2016;87(18):1871–1877. .
   PubMed Web of Science ®Google Scholar
• Friedman DI, Quiros PA, Subramanian PS, et al. Headache in idiopathic intracranial hypertension: findings from the idiopathic intracranial hypertension treatment trial. Headache. 2017;57(8):1195–1205. .
   PubMed Web of Science ®Google Scholar
• Wall M, Kupersmith MJ, Thurtell MJ, et al. The longitudinal idiopathic intracranial hypertension trial: outcomes from Months 6 – 12. Am J Ophthalmol. 2017;176:102–107.
   PubMed Web of Science ®Google Scholar
• Hornby C, Mollan SP, Botfield H, et al. Metabolic concepts in idiopathic intracranial hypertension and their potential for therapeutic intervention. J Neuroophthalmol. 2018;38(4):522–530.
   PubMed Web of Science ®Google Scholar
• O’Reilly MW, Westgate CS, Hornby C, et al. A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics. JCI Insight. 2019 Mar 21;4(6):e125348.
   PubMed Web of Science ®Google Scholar
• Westgate CS, Botfield HF, Alimajstorovic Z, et al. Systemic and adipocyte transcriptional and metabolic dysregulation in idiopathic intracranial hypertension. JCI Insight. 2021;13:145346.
   Web of Science ®Google Scholar
• Alimajstorovic Z, Westgate CSJ, Jensen RH, et al. Guide to preclinical models used to study the pathophysiology of idiopathic intracranial hypertension. Eye (Lond). 2020;34(8):1321–1333.
   PubMed Web of Science ®Google Scholar
• Hamedani AG, Thibault DP, Revere KE, et al. Trends in the surgical treatment of pseudotumor cerebri syndrome in the United States. JAMA Network Open. 2020;3(12):e2029669.
   PubMed Web of Science ®Google Scholar
• Dinkin M, Oliveira C. Men are from mars, idiopathic intracranial hypertension is from venous: the role of venous sinus stenosis and stenting in idiopathic intracranial hypertension. Semin Neurol. 2019;39(6):692–703.
   PubMed Web of Science ®Google Scholar
• Mollan SP, Hornby C, Mitchell J, et al. Evaluation and management of adult idiopathic intracranial hypertension. Pract Neurol. 2018;18(6):485–488.
   PubMedGoogle Scholar
• Botfield HF, Uldall MS, Westgate CSJ, et al. A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus. Sci Transl Med. 2017 Aug 23;9(404):eaan0972.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Bailey TS, Billings LK. STEP 3 investigators. effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioural therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021 Feb 24;325(14):1403.
   Web of Science ®Google Scholar